Literature DB >> 17177141

Expression and distribution of prolactin receptor in normal, fibrotic, and cirrhotic human liver.

J Simon-Holtorf1, H Mönig, H-J Klomp, A Reinecke-Lüthge, U R Fölsch, S Kloehn.   

Abstract

Liver cirrhosis is often associated with elevated levels of prolactin (PRL). This is commonly attributed to impaired hepatic metabolism of estrogens. However, there is evidence suggesting that PRL may be an important factor in hepatic tissue regeneration. To investigate the role of PRL in the pathogenesis of liver cirrhosis, we used RT-PCR and immunhistochemical staining to analyze changes in the expression and the histological distribution of the prolactin receptor (PRLR) in normal, fibrotic and cirrhotic hepatic tissue. Liver tissue was obtained from 29 surgically explanted human livers. The histological examination demonstrated normal liver tissue (n=9) as well as different grades of fibrosis (n=10) and cirrhosis (n=10). In liver cirrhosis and fibrosis, PRLR-mRNA was expressed at a higher level compared to normal liver specimens. Immunohistochemical staining of normal liver tissue demonstrated homogeneous distribution of the PRLR in the hepatocytes and in the epithelial cells of the bile ducts. This pattern of distribution was lost in fibrosis, where an accumulation of the PRLR was observed in the damaged hepatocytes. As no PRL-mRNA was detectable in normal, fibrotic or cirrhotic tissue, PRL does not act through autocrine or paracrine mechanisms. These data confirm previous results, which we obtained using an animal model for experimental liver cirrhosis in rats suggesting a metabolic function of PRL in normal liver and a regenerative function in fibrotic and cirrhotic liver. In conclusion, PRL might be involved in the pathogenesis of liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17177141     DOI: 10.1055/s-2006-948310

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

Review 1.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

2.  Gastric estrogen increases pituitary estrogen receptor α and prolactin mRNAs during the different pathological conditions of the liver.

Authors:  Hiroto Kobayashi; Saori Yoshida; Ying-Jie Sun; Nobuyuki Shirasawa; Akira Naito
Journal:  Endocrine       Date:  2012-07-28       Impact factor: 3.633

3.  Prolactin promotes hepatocellular carcinoma through Janus kinase 2.

Authors:  Yao-Tsung Yeh; King-Teh Lee; Chia-Jung Tsai; Yu-Jie Chen; Shen-Nien Wang
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

4.  Domperidone use and risk of primary liver cancer in the Clinical Practice Research Datalink.

Authors:  Jake E Thistle; Jessica L Petrick; Baiyu Yang; Marie C Bradley; Barry I Graubard; Katherine A McGlynn
Journal:  Cancer Epidemiol       Date:  2018-07-06       Impact factor: 2.984

Review 5.  Male hypogonadism in cirrhosis and after liver transplantation.

Authors:  C Foresta; M Schipilliti; F A Ciarleglio; A Lenzi; D D'Amico
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

6.  Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis.

Authors:  Sarah Byberg; Jesper Futtrup; Mikkel Andreassen; Jesper Krogh
Journal:  Endocr Connect       Date:  2019-10       Impact factor: 3.335

7.  Gene expression changes induced by the tumorigenic pyrrolizidine alkaloid riddelliine in liver of Big Blue rats.

Authors:  Nan Mei; Lei Guo; Ruqing Liu; James C Fuscoe; Tao Chen
Journal:  BMC Bioinformatics       Date:  2007-11-01       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.